Department of Clinical Science and Education, Södersjukhuset AB, Karolinska Institutet, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Clin Endocrinol (Oxf). 2021 Sep;95(3):520-526. doi: 10.1111/cen.14497. Epub 2021 May 30.
Diuretics are often implicated in hyponatraemia. While thiazides constitute one of the most common causes of hyponatraemia, data on loop diuretics and potassium-sparing agents are limited and partly conflicting. The objective of this investigation was to study the association between use of different types of non-thiazide diuretics and hospitalization due to hyponatraemia.
DESIGN, PATIENTS AND MEASUREMENTS: This was a register-based case-control study on the adult Swedish population. By linking national registers, patients hospitalized with a principal diagnosis of hyponatraemia (n = 11,213) from 1 October 2005 through 31 December 2014 were compared with matched controls (n = 44,801). Multivariable logistic regression, adjusted for multiple confounders, was used to analyse the association between use of diuretics and hyponatraemia. In addition, newly initiated use (≤90 days) and ongoing use were examined separately.
Adjusted odds ratios (aORs) (95% CI) were 0.61 (0.57-0.66) for the use of furosemide, 1.69 (1.54-1.86) for the use of amiloride and 1.96 (1.78-2.18) for the use of spironolactone and hospitalization due to hyponatraemia. For newly initiated therapy, aORs ranged from 1.23 (1.04-1.47) for furosemide to 3.55 (2.75-4.61) for spironolactone. The aORs for ongoing use were 0.52 (0.47-0.57) for furosemide, 1.62 (1.47-1.79) for amiloride and 1.75 (1.56-1.98) for spironolactone.
Ongoing use of furosemide was inversely correlated with hospitalization due to hyponatraemia, suggesting a protective effect. Consequently, if treatment with furosemide precedes the development of hyponatraemia by some time, other causes of hyponatraemia should be sought. Spironolactone and amiloride may both contribute to hyponatraemia; this effect is most prominent early in treatment.
利尿剂常与低钠血症有关。噻嗪类利尿剂是低钠血症最常见的原因之一,而关于袢利尿剂和保钾利尿剂的数据有限且部分相互矛盾。本研究旨在研究不同类型非噻嗪类利尿剂的使用与低钠血症住院之间的关系。
设计、患者和测量方法:这是一项基于登记的瑞典成年人群病例对照研究。通过链接国家登记册,比较了 2005 年 10 月 1 日至 2014 年 12 月 31 日期间因低钠血症(n=11213)主要诊断住院的患者与 44801 名匹配对照者(n=44801)。使用多变量逻辑回归,调整了多个混杂因素,分析了利尿剂使用与低钠血症之间的关系。此外,还分别检查了新起始使用(≤90 天)和持续使用。
调整后的比值比(aOR)(95%可信区间)分别为 0.61(0.57-0.66),0.61(0.57-0.66),0.61(0.57-0.66)。(0.61)(0.57-0.66)。0.61(0.57-0.66)用于呋塞米,1.69(1.54-1.86)用于阿米洛利,1.96(1.78-2.18)用于螺内酯,用于因低钠血症住院。对于新起始治疗,呋塞米的 aOR 范围为 1.23(1.04-1.47),螺内酯为 3.55(2.75-4.61)。持续使用的 aOR 分别为呋塞米 0.52(0.47-0.57)、阿米洛利 1.62(1.47-1.79)和螺内酯 1.75(1.56-1.98)。
持续使用呋塞米与因低钠血症住院呈负相关,提示具有保护作用。因此,如果呋塞米的治疗先于低钠血症的发生一段时间,应寻找其他低钠血症的原因。螺内酯和阿米洛利都可能导致低钠血症;这种作用在治疗早期最为明显。